Join us for a virtual fireside chat with visionaries in biopharma! We’re
bringing together biopharma key option leaders recognized for their
contributions to innovative human disease research and translational
safety to share their thoughts on technologies that are transforming
drug discovery.
3D cell-based assays, including organoids, spheroids, and advanced organ-on-chip systems, have grown in popularity in the scientific community. Compared to conventional 2D assays, 3D assays deliver more biological relevance, more closely mimic the tissue microenvironment, and offer extended culturing necessary to assess physiological drug effects. Still, their use in larger-scale drug screening programs is limited, despite these clear advantages.
In this discussion, Dr. Terry Riss from Promega, Dr. Tim Spicer from Scripps Research, and Dr. Jan Lichtenberg from InSphero explored the latest state-of-the-art automated 3D cell-based assays and focused on progress and obstacles on the way to fully automated screening in 3D. During the event, our panelists address questions and topics, such as:
- What are the advantages of moving to phenotypic screens in 3D?
- How do you choose the right 3D modality (spheroid, organoid, other scaffold-based approaches) and supporting cells, for your research?
- How do you select assays (biochemical vs. imaging vs. omics) from 3D models that automate well, and deliver consistent results?
- Use cases for automated 3D cell-based assays in the drug R&D process, safety vs. discovery
- What are the key hurdles, and how do we overcome them?
3 May 2021
T1D: Emerging Perspectives on Disease Pathogenesis, Prevention and Treatment
Our understanding of the human T1D etiology along with proposed therapeutic options has greatly advanced during the last decades. Nevertheless, the rate of bench to bedside translation is still disappointingly slow. During the discussion, our panelists explored key topics on:
Major discoveries and knowledge gaps in our understanding of T1D pathogenesis.
Emerging therapies to treat or prevent T1D, and their potential challenges.
23 Apr 2021
Does Physiological Complexity Kill Scalability?
During this roundtable about industrial applications for complex, yet scalable in vitro models for drug discovery, we discussed the importance of balancing experimental complexity and scalability, and how thoughtful engineering can ensure successful translation from academia to industry.
Our panelists explored key topics, such as:
Why are biological complexity and experimental scalability both essential for producing meaningful and robust datasets?
What are the trade-offs between complexity and scalability?
In which stages of research and development are scalability most critical?
How does scalability of complex systems influence drug development?
What are the next steps to ensure translatability of complex model systems?
10 Feb 2021
Animal-Free Drug Safety Testing: Challenges and Opportunities
New Frontiers in 3D Visionaries Speak roundtable
Episode 1: Animal-Free Drug Safety Testing: Challenges and Opportunities
Drug safety testing is an essential part of drug R&D. New drug candidates must be tested in animals before they can enter first-in-human trials. The current animal testing paradigm has proven advantages as well as significant weaknesses. Alternative methods are increasingly being used to compensate for these weaknesses. In this roundtable, our panelists discuss challenges and opportunities for applying in vitro and in silico models in drug development to improve translation to patients. Panelists: Dr. Stefan Platz from AstraZeneca, Prof. Thomas Hartung of Johns Hopkins University Bloomberg School of Public Health, and Prof. Armin Wolf from InSphero AG.
Host of New Frontiers in 3D | Visionaries Speak?
Claim your podcast to manage its listing and keep your show details accurate.
Pod Engine is an independent podcast discovery and analytics service and is not affiliated with or endorsed by this podcast. Artwork and show content belong to their owners. Full legal notice.
